Sector News

400 Novartis workers prepare for job losses at U.K. manufacturing site

February 13, 2020
Life sciences

CEO Vas Narasimhan recently told investors Novartis is well along toward its goal of consolidating its manufacturing into one “that’s much more focused on high-end technologies.”

One of the facilities that is in the path of that advancement is the company’s Grimsby, U.K. operation where about 400 workers are set to lose their jobs unless a buyer can be found for the site.

Taskforce members made up of workers, local officials and Novartis met today for an update on how the closing process will proceed if a buyer does not materialize, BusinessLive reports. The task force was formed to aid workers and the town with job losses after the closing was first announced in 2018.

Novartis last fall said half-a-dozen companies had sized up the site for a possible purchase but nothing has been announced since.

Novartis intends to begin layoffs in April with the closure of one facility at the site and wind down the rest of the operation by the end of the year.

A site in Ireland is also being downsized. The drugmaker announced in the fall that it will close a production facility at the Ringaskiddy site in Ireland by mid-2022 as it consolidates its active pharmaceutical ingredient operations there.

Novartis has been closing and selling off bulk and formulation manufacturing facilities as it shifts to high-margin specialized drugs like cell and gene therapies and away from older meds and generics.

“We also are advancing our efforts in procurement and manufacturing, and are really reducing the excess inventories that we’re holding and also deploying data and digital much more aggressively across the manufacturing network,” Narasimhan said on an earnings call two weeks ago.

By Eric Palmer

Source: Fierce Pharma

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]